Antibody Persistence and Booster Responses to Split-Virion H5N1 Avian Influenza Vaccine in Young and Elderly Adults

Rajeka Lazarus; Sarah Kelly; Matthew D Snape; Corinne Vandermeulen; Merryn Voysey; Karel Hoppenbrouwers; Annick Hens; Pierre Van Damme; Stephanie Pepin; Isabel Leroux-Roels; Geert Leroux-Roels; Andrew J Pollard

doi:10.1371/journal.pone.0165384

Antibody Persistence and Booster Responses to Split-Virion H5N1 Avian Influenza Vaccine in Young and Elderly Adults

Rajeka Lazarus, Sarah Kelly, Matthew D Snape, Corinne Vandermeulen, Merryn Voysey, Karel Hoppenbrouwers, Annick Hens, Pierre Van Damme, Stephanie Pepin, Isabel Leroux-Roels, Geert Leroux-Roels, Andrew J Pollard

School of Education

Research output: Contribution to journal › Article (Academic Journal) › peer-review

3 Citations (Scopus)

Abstract

UNLABELLED: Avian influenza continues to circulate and remains a global health threat not least because of the associated high mortality. In this study antibody persistence, booster vaccine response and cross-clade immune response between two influenza A(H5N1) vaccines were compared. Participants aged over 18-years who had previously been immunized with a clade 1, A/Vietnam vaccine were re-immunized at 6-months with 7.5 μg of the homologous strain or at 22-months with a clade 2, alum-adjuvanted, A/Indonesia vaccine. Blood sampled at 6, 15 and 22-months after the primary course was used to assess antibody persistence. Antibody concentrations 6-months after primary immunisation with either A/Vietnam vaccine 30 μg alum-adjuvanted vaccine or 7.5 μg dose vaccine were lower than 21-days after the primary course and waned further with time. Re-immunization with the clade 2, 30 μg alum-adjuvanted vaccine confirmed cross-clade reactogenicity. Antibody cross-reactivity between A(H5N1) clades suggests that in principle a prime-boost vaccination strategy may provide both early protection at the start of a pandemic and improved antibody responses to specific vaccination once available.

TRIAL REGISTRATION: ClinicalTrials.gov NCT00415129.

Original language	English
Pages (from-to)	e0165384
Journal	PLoS ONE
Volume	11
Issue number	11
DOIs	https://doi.org/10.1371/journal.pone.0165384
Publication status	Published - 1 Jan 2016

Keywords

Adjuvants, Immunologic/administration & dosage
Adolescent
Adult
Animals
Antibodies, Viral/immunology
Antibody Formation/immunology
Birds/immunology
Humans
Immunization, Secondary/methods
Indonesia
Influenza A Virus, H5N1 Subtype/immunology
Influenza Vaccines/immunology
Influenza in Birds/immunology
Influenza, Human/immunology
Male
Middle Aged
Neutralization Tests/methods
Vaccination/methods
Vietnam
Virion/immunology
Young Adult

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1371/journal.pone.0165384

Handle.net

Persistent link

Cite this

Lazarus, R., Kelly, S., Snape, M. D., Vandermeulen, C., Voysey, M., Hoppenbrouwers, K., Hens, A., Van Damme, P., Pepin, S., Leroux-Roels, I., Leroux-Roels, G., & Pollard, A. J. (2016). Antibody Persistence and Booster Responses to Split-Virion H5N1 Avian Influenza Vaccine in Young and Elderly Adults. PLoS ONE, 11(11), e0165384. https://doi.org/10.1371/journal.pone.0165384

@article{d4889f8df23947a89b228eda318f7006,

title = "Antibody Persistence and Booster Responses to Split-Virion H5N1 Avian Influenza Vaccine in Young and Elderly Adults",

abstract = "UNLABELLED: Avian influenza continues to circulate and remains a global health threat not least because of the associated high mortality. In this study antibody persistence, booster vaccine response and cross-clade immune response between two influenza A(H5N1) vaccines were compared. Participants aged over 18-years who had previously been immunized with a clade 1, A/Vietnam vaccine were re-immunized at 6-months with 7.5 μg of the homologous strain or at 22-months with a clade 2, alum-adjuvanted, A/Indonesia vaccine. Blood sampled at 6, 15 and 22-months after the primary course was used to assess antibody persistence. Antibody concentrations 6-months after primary immunisation with either A/Vietnam vaccine 30 μg alum-adjuvanted vaccine or 7.5 μg dose vaccine were lower than 21-days after the primary course and waned further with time. Re-immunization with the clade 2, 30 μg alum-adjuvanted vaccine confirmed cross-clade reactogenicity. Antibody cross-reactivity between A(H5N1) clades suggests that in principle a prime-boost vaccination strategy may provide both early protection at the start of a pandemic and improved antibody responses to specific vaccination once available.TRIAL REGISTRATION: ClinicalTrials.gov NCT00415129.",

keywords = "Adjuvants, Immunologic/administration & dosage, Adolescent, Adult, Animals, Antibodies, Viral/immunology, Antibody Formation/immunology, Birds/immunology, Humans, Immunization, Secondary/methods, Indonesia, Influenza A Virus, H5N1 Subtype/immunology, Influenza Vaccines/immunology, Influenza in Birds/immunology, Influenza, Human/immunology, Male, Middle Aged, Neutralization Tests/methods, Vaccination/methods, Vietnam, Virion/immunology, Young Adult",

author = "Rajeka Lazarus and Sarah Kelly and Snape, {Matthew D} and Corinne Vandermeulen and Merryn Voysey and Karel Hoppenbrouwers and Annick Hens and {Van Damme}, Pierre and Stephanie Pepin and Isabel Leroux-Roels and Geert Leroux-Roels and Pollard, {Andrew J}",

year = "2016",

month = jan,

day = "1",

doi = "10.1371/journal.pone.0165384",

language = "English",

volume = "11",

pages = "e0165384",

journal = "PLoS ONE",

issn = "1932-6203",

publisher = "Public Library of Science",

number = "11",

}

Lazarus, R, Kelly, S, Snape, MD, Vandermeulen, C, Voysey, M, Hoppenbrouwers, K, Hens, A, Van Damme, P, Pepin, S, Leroux-Roels, I, Leroux-Roels, G & Pollard, AJ 2016, 'Antibody Persistence and Booster Responses to Split-Virion H5N1 Avian Influenza Vaccine in Young and Elderly Adults', PLoS ONE, vol. 11, no. 11, pp. e0165384. https://doi.org/10.1371/journal.pone.0165384

TY - JOUR

T1 - Antibody Persistence and Booster Responses to Split-Virion H5N1 Avian Influenza Vaccine in Young and Elderly Adults

AU - Lazarus, Rajeka

AU - Kelly, Sarah

AU - Snape, Matthew D

AU - Vandermeulen, Corinne

AU - Voysey, Merryn

AU - Hoppenbrouwers, Karel

AU - Hens, Annick

AU - Van Damme, Pierre

AU - Pepin, Stephanie

AU - Leroux-Roels, Isabel

AU - Leroux-Roels, Geert

AU - Pollard, Andrew J

PY - 2016/1/1

Y1 - 2016/1/1

N2 - UNLABELLED: Avian influenza continues to circulate and remains a global health threat not least because of the associated high mortality. In this study antibody persistence, booster vaccine response and cross-clade immune response between two influenza A(H5N1) vaccines were compared. Participants aged over 18-years who had previously been immunized with a clade 1, A/Vietnam vaccine were re-immunized at 6-months with 7.5 μg of the homologous strain or at 22-months with a clade 2, alum-adjuvanted, A/Indonesia vaccine. Blood sampled at 6, 15 and 22-months after the primary course was used to assess antibody persistence. Antibody concentrations 6-months after primary immunisation with either A/Vietnam vaccine 30 μg alum-adjuvanted vaccine or 7.5 μg dose vaccine were lower than 21-days after the primary course and waned further with time. Re-immunization with the clade 2, 30 μg alum-adjuvanted vaccine confirmed cross-clade reactogenicity. Antibody cross-reactivity between A(H5N1) clades suggests that in principle a prime-boost vaccination strategy may provide both early protection at the start of a pandemic and improved antibody responses to specific vaccination once available.TRIAL REGISTRATION: ClinicalTrials.gov NCT00415129.

AB - UNLABELLED: Avian influenza continues to circulate and remains a global health threat not least because of the associated high mortality. In this study antibody persistence, booster vaccine response and cross-clade immune response between two influenza A(H5N1) vaccines were compared. Participants aged over 18-years who had previously been immunized with a clade 1, A/Vietnam vaccine were re-immunized at 6-months with 7.5 μg of the homologous strain or at 22-months with a clade 2, alum-adjuvanted, A/Indonesia vaccine. Blood sampled at 6, 15 and 22-months after the primary course was used to assess antibody persistence. Antibody concentrations 6-months after primary immunisation with either A/Vietnam vaccine 30 μg alum-adjuvanted vaccine or 7.5 μg dose vaccine were lower than 21-days after the primary course and waned further with time. Re-immunization with the clade 2, 30 μg alum-adjuvanted vaccine confirmed cross-clade reactogenicity. Antibody cross-reactivity between A(H5N1) clades suggests that in principle a prime-boost vaccination strategy may provide both early protection at the start of a pandemic and improved antibody responses to specific vaccination once available.TRIAL REGISTRATION: ClinicalTrials.gov NCT00415129.

KW - Adjuvants, Immunologic/administration & dosage

KW - Adolescent

KW - Adult

KW - Animals

KW - Antibodies, Viral/immunology

KW - Antibody Formation/immunology

KW - Birds/immunology

KW - Humans

KW - Immunization, Secondary/methods

KW - Indonesia

KW - Influenza A Virus, H5N1 Subtype/immunology

KW - Influenza Vaccines/immunology

KW - Influenza in Birds/immunology

KW - Influenza, Human/immunology

KW - Male

KW - Middle Aged

KW - Neutralization Tests/methods

KW - Vaccination/methods

KW - Vietnam

KW - Virion/immunology

KW - Young Adult

U2 - 10.1371/journal.pone.0165384

DO - 10.1371/journal.pone.0165384

M3 - Article (Academic Journal)

C2 - 27814377

SN - 1932-6203

VL - 11

SP - e0165384

JO - PLoS ONE

JF - PLoS ONE

IS - 11

ER -

Antibody Persistence and Booster Responses to Split-Virion H5N1 Avian Influenza Vaccine in Young and Elderly Adults

Abstract

Keywords

UN SDGs

Access to Document

Handle.net

Fingerprint

Cite this